...
APLSMID

Apellis Pharmaceuticals, Inc.

HealthcareBiotechnology
$20.96
$0.01(-3.14%)
52W$16.10
$30.48
FinancialsValuationvs ARGX
Updated Mar 3, 12:00 AM
RSI44
RS Rating30/99
Beta0.84
Volatility64%
F-Score6/9
Mkt Cap$2.7B
WEAKENING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

WEAKENING

Apellis Pharmaceuticals, Inc. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 30), showing significant lag compared to the market leaders. Earnings contraction of 124% provides fundamental context to the price action. Investors should exercise caution due to high volatility (64% annualized), which requires wider risk management.

Relative Strength
30
out of 99
Lagging
Trend Score
1/4
Minervini Criteria
WEAKENING
Risk (Beta)
0.84
vs S&P 500
DEFENSIVE
52W Position
34%
from 52W low
Lower Half
Trend & Momentum Analysis

Trend Template (Minervini)

WEAKENING1/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$23.08
50 SMA > 100 SMA$23.11
100 SMA > 150 SMA$23.69
150 SMA > 200 SMA$22.38

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$22.35-6.23%BELOW
50 SMA$23.08-9.20%BELOW
100 SMA$23.11-9.29%BELOW
150 SMA$23.69-11.51%BELOW
200 SMA$22.38-6.34%BELOW

Price Performance

1D-3.1%
1W-6.7%
1M-9.1%
3M-1.6%
6M-25.3%
YTD-18.9%
1Y-16.7%
3Y-31.6%
52-Week Trading Range34% from low
$20.96
52W Low$16.10
52W High$30.48

Technical Indicators

RSI (14)NEUTRAL
43.8
305070
VCP ScoreCOOL
4/10
Base depth: 39.1%

Risk Profile

Beta
0.84
52W Vol
64%
ATR
$1.00
Max DD (1Y)
-37%

Volume Analysis

Today
20
50D Avg
2.55M
Vol Ratio
0.00x
Liquidity
LIQUID

Earnings Momentum

Q1'25-37%
$-0.74
Q2'25-10%
$-0.33
Q3'25+472%
$1.71
Q4'25-124%
$-0.65
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:—
5 Years:+22.43%
3 Years:+109.08%
TTM:-11.77%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+99.37%

Stock Price CAGR

10 Years:+4.10%
5 Years:-15.16%
3 Years:-31.59%
1 Year:-16.66%

Return on Equity

10Y Avg:-193.5%
5Y Avg:-220.1%
3Y Avg:-125.4%
Last Year:7.5%

Key Metrics

Market Cap$2.7B
Gross Margin85.2%
Net Margin3.2%
Piotroski F-Score6/9

More APLS Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

APLS vs ARGXARGXCANFAKTXABVX

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 30 meansAPLS outperformed 30% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.84 means 16% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 6/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 4/10 with COOL status.

Frequently Asked Questions

Is APLS in an uptrend right now?

APLS has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.

Is APLS overbought or oversold?

APLS's RSI (14) is 44. The stock is in neutral territory, neither overbought nor oversold.

Is APLS outperforming the market?

APLS has a Relative Strength (RS) Rating of 30 out of 99. APLS is currently lagging the broader market.

Where is APLS in its 52-week range?

APLS is trading at $20.96, which is 69% of its 52-week high ($30.48) and 34% above its 52-week low ($16.10).

How volatile is APLS?

APLS has a Beta of 0.84 and 52-week volatility of 64%. It's less volatile than the S&P 500 - generally more stable.